Market Cap : 7.91 B | Enterprise Value : 7.34 B | PE Ratio : At Loss | PB Ratio : 18.21 |
---|
NAS:NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. NovoCure's goodwill for the quarter that ended in Mar. 2022 was $0.0 Mil.
The historical data trend for NovoCure's Goodwill can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
NovoCure's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
Goodwill-to-Asset (A: Dec. 2021 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 1139.495 | |
= | 0.00 |
NovoCure's Goodwill-to-Asset Ratio for the quarter that ended in Mar. 2022 is calculated as
Goodwill-to-Asset (Q: Mar. 2022 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 1150.21 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of NovoCure's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.
Weinberg Uri | officer: Chief Science Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Groenhuysen Wilhelmus Cm | officer: Chief Operating Officer | C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654 |
Danziger Asaf | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302 |
Leung Gabriel | director | C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960 |
Shah Pritesh | officer: Chief Commercial Officer | C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Leonard Frank X | officer: Chief Development Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Cordova Ashley | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Madden Martin J. | director | C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043 |
Benaim Ely | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 |
Doyle William F | director, officer: Executive Chairman | PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Ambrogi Michael J. | officer: Chief Operating Officer | 195 COMMERCE WAY PORTSMOUTH NH 03801 |
Longsworth Todd Christopher | officer: General Counsel | NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Hilleman Jeryl L | director | C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025 |
Mccoy Sherilyn S | director | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Hung David | director | C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
From GuruFocus
Other Sources
By Fool 2021-10-14
By Zacks 2022-02-24
By Zacks 2021-07-22
By Fool 2021-07-30
By Fool 2022-01-29
By Seekingalpha 2022-02-28
By Zacks 2021-10-28
By Fool 2022-01-20
By Zacks 2021-10-12
By Zacks 2022-02-16